journal article·2022-12Open access

Hybrid heart valves with VEGF-loaded zwitterionic hydrogel coating for improved anti-calcification and re-endothelialization

Qi Tong, Ao Sun, Zhengjie Wang, Tao Li, Xinye He, Yongjun Qian, Zhiyong Qian

Abstract

With the aging of the population in worldwide, valvular heart disease has become one of the most prominent life-threatening diseases in human health, and heart valve replacement surgery is one of the therapeutic methods for valvular heart disease. Currently, commercial bioprosthetic heart valves (BHVs) for clinical application are prepared with xenograft heart valves or pericardium crosslinked by glutaraldehyde. Due to the residual cell toxicity from glutaraldehyde, heterologous antigens, and immune response, there are still some drawbacks related to the limited lifespan of bioprosthetic heart valves, such as thrombosis, calcification, degeneration, and defectiveness of re-endothelialization. Therefore, the problems of calcification, defectiveness of re-endothelialization, and poor biocompatibility from the use of bioprosthetic heart valve need to be solved. In this study, hydrogel hybrid heart valves with improved anti-calcification and re-endothelialization were prepared by taking decellularized porcine heart valves as scaffolds following grafting with double bonds. Then, the anti-biofouling zwitterionic monomers 2-methacryloyloxyethyl phosphorylcholine (MPC) and vascular endothelial growth factor (VEGF) were utilized to obtain a hydrogel-coated hybrid heart valve (PEGDA-MPC-DHVs@VEGF). The results showed that fewer platelets and thrombi were observed on the surface of the PEGDA-MPC-DHVs@VEGF. Additionally, the PEGDA-MPC-DHVs@VEGF exhibited excellent collagen stability, biocompatibility and re-endothelialization potential. Moreover, less calcification deposition and a lower immune response were observed in the PEGDA-MPC-DHVs@VEGF compared to the glutaraldehyde-crosslinked DHVs (Glu-DHVs) after subcutaneous implantation in rats for 30 days. These studies demonstrated that the strategy of zwitterionic hydrogels loaded with VEGF may be an effective approach to improving the biocompatibility, anti-calcification and re-endothelialization of bioprosthetic heart valves.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cardiac Valve Diseases and Treatments · Aortic Disease and Treatment Approaches · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (62)

Show source-provided references
1. The future of heart valve replacement: recent developments and translational challenges for heart valve tissue engineering10.1002/term.2326 ↗
2. Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity10.1038/s41569-020-0422-8 ↗
3. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends10.1016/S0140-6736(09)60780-7 ↗
4. The 2020 ACC/AHA guidelines for management of patients with valvular heart disease: highlights and perioperative implications10.1053/j.jvca.2021.04.013 ↗
5. A method for simultaneously crosslinking and functionalizing extracellular matrix-based biomaterials as bioprosthetic heart valves with enhanced endothelialization and reduced inflammation10.1016/j.actbio.2020.10.029 ↗
6. Long-term stability and biocompatibility of pericardial bioprosthetic heart valves10.3389/fcvm.2021.728577 ↗
7. Subclinical leaflet thrombosis after transcatheter aortic valve implantation10.1136/heartjnl-2017-311818 ↗
8. Subclinical leaflet thrombosis after transcatheter aortic valve replacement: a meta-analysis10.1016/j.jcin.2021.09.019 ↗
9. Structural valve deterioration and mode of failure of stentless bioprosthetic valves10.1016/j.carpath.2020.107301 ↗
10. Noncalcific mechanisms of bioprosthetic structural valve degeneration
11. Mechanisms and drug therapies of bioprosthetic heart valve calcification10.3389/fphar.2022.909801 ↗
12. Bioengineered percutaneous heart valves for transcatheter aortic valve replacement: a comparative evaluation of decellularised bovine and porcine pericardia10.1016/j.msec.2021.111936 ↗
13. Mechanical versus bioprosthetic aortic valve replacement10.1093/eurheartj/ehx141 ↗
14. A novel detergent-based decellularization combined with carbodiimide crosslinking for improving anti-calcification of bioprosthetic heart valve10.1088/1748-605X/ac0088 ↗
15. Decellularization and engineered crosslinking: a promising dual approach towards bioprosthetic heart valve longevity10.1093/ejcts/ezaa257 ↗
16. Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection10.1161/CIRCULATIONAHA.105.549311 ↗
17. Effects of glutaraldehyde concentration, pretreatment time, and type of tissue (porcine versus bovine) on postimplantation calcification10.1016/j.jtcvs.2011.09.043 ↗
18. Decellularized tissue-engineered heart valves calcification: what do animal and clinical studies tell us?10.1007/s10856-020-06462-x ↗
19. Epoxy chitosan-crosslinked acellular bovine pericardium with improved anti-calcification and biological properties10.1021/acsabm.0c00067 ↗
20. A riboflavin-ultraviolet light A-crosslinked decellularized heart valve for improved biomechanical properties, stability, and biocompatibility10.1039/C9BM01956A ↗
21. Polyzwitterion-crosslinked hybrid tissue with antithrombogenicity, endothelialization, anticalcification properties10.1016/j.cej.2020.128244 ↗
22. Zwitterionic hydrogel-coated heart valves with improved endothelialization and anti-calcification properties10.1016/j.msec.2021.112329 ↗
23. An injectable conductive hydrogel restores electrical transmission at myocardial infarct site to preserve cardiac function and enhance repair
24. A PEGylation method of fabricating bioprosthetic heart valves based on glutaraldehyde and 2-amino-4-pentenoic acid co-crosslinking with improved antithrombogenicity and cytocompatibility10.1016/j.actbio.2022.03.026 ↗
25. Endothelialization of cardiovascular devices10.1016/j.actbio.2019.08.042 ↗
26. Endothelialization of implanted cardiovascular biomaterial surfaces: the development from in vitro to in vivo10.1002/jbm.a.35025 ↗
27. Pediatric tubular pulmonary heart valve from decellularized engineered tissue tubes10.1016/j.biomaterials.2015.05.009 ↗
28. Radical polymerization-crosslinking method for improving extracellular matrix stability in bioprosthetic heart valves with reduced potential for calcification and inflammatory response10.1016/j.actbio.2018.10.017 ↗
29. Cross-linking porcine pericardium by 3,4-dihydroxybenzaldehyde: a novel method to improve the biocompatibility of bioprosthetic valve10.1021/acs.biomac.0c01554 ↗
30. Nonglutaraldehyde fixation for off the shelf decellularized bovine pericardium in anticalcification cardiac valve applications10.1021/acsbiomaterials.8b01311 ↗
31. Inorganic-polymerization crosslinked tissue-siloxane hybrid as potential biomaterial for bioprosthetic heart valves10.1002/jbm.a.37061 ↗
32. Optimizing glutaraldehyde-fixed tissue heart valves with chondroitin sulfate hydrogel for endothelialization and shielding against deterioration10.1021/acs.biomac.8b00077 ↗
33. Biocompatibility and anti-calcification of a biological artery immobilized with naturally-occurring phytic acid as the crosslinking agent10.1039/C7TB02090B ↗
34. A bioprosthetic heart valve cross-linked by a non-glutaraldehyde reagent with improved biocompatibility, endothelialization, anti-coagulation and anti-calcification properties10.1039/D1TB00409C ↗
35. Combined anticalcification treatment of bovine pericardium with decellularization and hyaluronic acid derivative
36. Heart valve tissue engineering: an overview of heart valve decellularization processes10.2217/rme-2017-0061 ↗
37. Strategies for development of decellularized heart valve scaffolds for tissue engineering10.1016/j.biomaterials.2022.121675 ↗
38. Endothelialization of polycaprolactone vascular graft under the action of locally applied vascular endothelial growth factor10.1007/s10517-018-4144-4 ↗
39. Hybrid pericardium with VEGF-loaded hyaluronic acid hydrogel coating to improve the biological properties of bioprosthetic heart valves10.1002/mabi.201800390 ↗
40. Fucoidan/VEGF-based surface modification of decellularized pulmonary heart valve improves the antithrombotic and re-endothelialization potential of bioprostheses10.1016/j.biomaterials.2018.01.054 ↗
41. Bioinspired engineering of poly(ethylene glycol) hydrogels and natural protein fibers for layered heart valve constructs10.1021/acsami.7b03281 ↗
42. Elastic compliance of fibrillar assemblies in type I collagen10.1016/j.bpc.2018.05.007 ↗
43. The blood compatibility challenge. Part 1: blood-contacting medical devices: the scope of the problem10.1016/j.actbio.2019.06.021 ↗
44. Prosthetic heart valve thrombosis10.1016/j.jacc.2016.09.958 ↗
45. Highly antifouling, biocompatible and tough double network hydrogel based on carboxybetaine-type zwitterionic polymer and alginate10.1016/j.carbpol.2021.117627 ↗
46. Integrating zwitterionic polymer and Ag nanoparticles on polymeric membrane surface to prepare antifouling and bactericidal surface via Schiff-based layer-by-layer assembly10.1016/j.jcis.2017.09.071 ↗
47. A GelMA-PEGDA-nHA composite hydrogel for bone tissue engineering10.3390/ma13173735 ↗
48. Enzyme-responsive hydrogel microparticles for pulmonary drug delivery10.1021/am501754s ↗
49. Hydrophilic polymer-based anti-biofouling coatings: preparation, mechanism, and durability10.1016/j.cis.2020.102264 ↗
50. Functional zwitterionic polymers on surface: structures and applications10.1002/asia.202000547 ↗
51. Bioinspired dopamine and zwitterionic polymers for non-fouling surface engineering10.1039/D1CS00658D ↗
52. Thrombogenic and inflammatory reactions to biomaterials in medical devices10.3389/fbioe.2020.00123 ↗
53. Hydrogel hybrid porcine pericardium for the fabrication of a pre-mounted TAVI valve with improved biocompatibility10.1039/C8TB02565G ↗
54. A review of the immune response stimulated by xenogenic tissue heart valves10.1111/sji.13018 ↗
55. Biochemical and histological evidence of deteriorated bioprosthetic valve leaflets: the accumulation of fibrinogen and plasminogen10.1242/bio.034009 ↗
56. Molecular pathways of cell-mediated degradation of fibrillar collagen10.1016/j.matbio.2017.11.008 ↗
57. Osteonectin regulates the extracellular matrix mineralization of osteoblasts through P38 signaling pathway10.1002/jcp.29131 ↗
58. Macrophages in inflammation, repair and regeneration10.1093/intimm/dxy054 ↗
59. M1 and M2 macrophages: oracles of health and disease10.1615/CritRevImmunol.v32.i6.10 ↗
60. Calcification and oxidative modifications are associated with progressive bioprosthetic heart valve dysfunction
61. Artificial heart valves with balanced charged networks exhibiting anti-calcification properties10.1021/acsabm.9b00902 ↗
62. Heart valves cross-linked with erythrocyte membrane drug-loaded nanoparticles as a biomimetic strategy for anti-coagulation, anti-inflammation, anti-calcification, and endothelialization10.1021/acsami.0c12688 ↗